OncoMatch/Clinical Trials/NCT05385549
5 Years of Adjuvant Imatinib in Patients With Gastrointestinal Stromal Tumor With a High Risk
Is NCT05385549 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Imatinib Mesylate for gastrointestinal stromal tumors.
Treatment: Imatinib Mesylate — In this study, the investigators aim to investigate the efficacy and safety of 5 years of adjuvant imatinib treatment in patients with tumor rupture defined by Nishida classification or those with a tumor size 10cm or larger and a mitotic index of 10/50HPFs or higher.
Check if I qualifyExtracted eligibility criteria
Cancer type
Gastrointestinal Stromal Tumor
Biomarker criteria
Required: KIT mutation
mutation in KIT or PDGFRα gene
Required: PDGFRA mutation
mutation in KIT or PDGFRα gene
Excluded: PDGFRA D842V
The patients with PDGFRα D842V mutation
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Lab requirements
Blood counts
neutrophil >1,500/mm3; platelet > 100,000/mm3; hemoglobin >8.0 g/dl
Kidney function
creatinine <1.5 x uln
Liver function
total bilirubin < 1.5 x uln; ast/alt < 2.5 x uln
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify